An open-label, Phase 1/2 clinical trial will evaluate the safety and efficacy of rigosertib in treating recessive dystrophic epidermolysis bullosa…
Articles by Forest Ray PhD
A new and easy-to-use algorithm may help physicians diagnose epidermolysis bullosa aquisita (EBA) sooner, a process that now can…
Ways to improve the quality of life for people with epidermolysis bullosa (EB) are needed, as those living with…
A distinct set of bacteria colonizes the skin in and around wounds in people with dystrophic epidermolysis bullosa (DEB),…
The first patient has been dosed in a Phase 2 trial investigating rigosertib as a treatment for cases of…
Krystal Biotech announced the full enrollment of a pivotal Phase 3 clinical trial of its topical gene therapy B-VEC…
Skin-derived stem cells producing the ABCB5 protein outperformed those derived from bone marrow at migrating toward and integrating into wounds…
Abeona Therapeutics will proceed with enrollment for its pivotal Phase 3 study of EB-101 as a treatment for…
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AP103, a potential topical…
Tonight at 8 p.m. EST, Jill and Eddie Vedder will host Venture Into Cures, a virtual event to raise…
Filsuvez, a topical gel by Amryt Pharma, raises the probability of complete wound closure while reducing the time that wounds…